The best-supported peptides for metabolic syndrome are the GLP-1-based obesity drugs, used on top of lifestyle change. Semaglutide 2.4 mg cut heart attacks, strokes and cardiovascular deaths by 20% in adults with heart disease and excess weight (6.5% vs 8.0%), and tirzepatide produced up to 20.9% weight loss with improvements in every cardiometabolic measure tested.[3][5] No drug is approved for metabolic syndrome itself, and “metabolic” research peptides such as MOTS-c have no human outcome data.[11][12]
For background on the drug class, see our GLP-1 basics hub and how GLP-1 drugs work.
What is metabolic syndrome?
Metabolic syndrome is a cluster of risk factors that together raise the chance of heart disease, stroke and type 2 diabetes. The common American Heart Association and NHLBI definition counts five measures, and three or more confirms the diagnosis:[1]
- a large waist (40 inches or more in men, 35 inches or more in women in the US)
- triglycerides of 150 mg/dL or higher
- low HDL cholesterol (below 40 mg/dL in men, 50 mg/dL in women)
- blood pressure of 130/85 or higher
- fasting glucose of 100 mg/dL or higher
Taking medicine for one of these also counts toward the definition.[1]
Evidence at a glance
| Peptide or drug | Evidence level | What was shown | FDA status | Our profile |
|---|---|---|---|---|
| Diet, activity and weight loss (standard care) | Human RCTs | 58% fewer new diabetes cases[2] | First-line care | — |
| Semaglutide 2.4 mg (Wegovy) | Human RCTs | 20% fewer major CV events in SELECT; 14.9% weight loss in STEP 1[3][4] | Approved for obesity and CV risk reduction, not “metabolic syndrome”[7] | Semaglutide |
| Tirzepatide (Zepbound) | Human RCTs | 15.0-20.9% weight loss; 1.3% vs 13.3% new diabetes over 3 years[5][6] | Approved for obesity and sleep apnea[8] | Tirzepatide |
| Tesamorelin (Egrifta) | FDA-approved for a narrow use | 15.2% less belly (visceral) fat in HIV lipodystrophy[10] | Approved only for HIV-related abdominal fat | Tesamorelin |
| MOTS-c | Animal or lab only | Less obesity and insulin resistance in mice[11] | Not approved[12] | MOTS-c |
| AOD-9604 | No evidence, marketing only | No metabolic syndrome trials | Not approved[12] | AOD-9604 |
Lifestyle change comes first
The strongest evidence for metabolic syndrome is for lifestyle change. In the Diabetes Prevention Program, adults with high blood sugar who joined an intensive diet and exercise program developed diabetes at 4.8 cases per 100 person-years, versus 7.8 on metformin and 11.0 on placebo. That is a 58% reduction with lifestyle and 31% with metformin.[2]
The trial enrolled 3,234 adults, followed them for an average of 2.8 years, and set modest goals: losing at least 7% of body weight and getting at least 150 minutes of physical activity a week. For every 6.9 people who joined the lifestyle program for three years, one case of diabetes was prevented.[2]
The American Heart Association’s Life’s Essential 8 lists the habits and measures behind heart health: diet, physical activity, nicotine exposure, sleep, body weight, cholesterol, blood sugar and blood pressure.[13] Each piece of metabolic syndrome can also be treated directly, for example with blood pressure or cholesterol medicines, and those treatments remain the foundation.
Semaglutide: the SELECT and STEP trials
Semaglutide copies the gut hormone GLP-1, which reduces appetite and improves blood sugar.
Weight and risk factors (STEP 1). Adults with overweight or obesity lost 14.9% of body weight on semaglutide 2.4 mg versus 2.4% on placebo over 68 weeks, with greater improvement in cardiometabolic risk factors.[4]
Heart outcomes (SELECT). SELECT enrolled 17,604 adults with established heart disease and overweight or obesity but without diabetes, a group in which metabolic syndrome is common. Over about 40 months, a heart attack, stroke or cardiovascular death occurred in 6.5% on semaglutide versus 8.0% on placebo, a 20% relative reduction. Side effects led 16.6% to stop the drug, versus 8.2% on placebo.[3]
Based on SELECT, Wegovy is approved to reduce the risk of major cardiovascular events in adults with established heart disease and obesity or overweight.[7] Our GLP-1 heart outcomes guide covers the wider evidence.
Tirzepatide: the SURMOUNT trials
Tirzepatide acts on both GIP and GLP-1 receptors.
SURMOUNT-1. Adults with obesity lost 15.0%, 19.5% and 20.9% of body weight on 5, 10 and 15 mg over 72 weeks, versus 3.1% on placebo. The authors reported improvements in all prespecified cardiometabolic measures.[5] The trial enrolled 2,539 adults without diabetes who had a BMI of 30 or more, or 27 or more with a weight-related health problem. Doses were raised over the first 20 weeks. Digestive side effects were the most common and mostly mild to moderate, occurring mainly while the dose was being increased.[5]
Diabetes prevention. In participants who also had prediabetes, three years of tirzepatide lowered the rate of new type 2 diabetes to 1.3%, versus 13.3% on placebo.[6]
Heart outcomes are still pending. SURMOUNT-MMO, a trial of about 15,000 adults testing whether tirzepatide reduces heart events and deaths, is ongoing with completion expected in 2027.[9] Zepbound is currently approved for weight management and obstructive sleep apnea.[8]
See our semaglutide vs tirzepatide guide to compare the two.
Tesamorelin: approved for one narrow use
Tesamorelin is a lab-made version of growth hormone-releasing hormone. In a 26-week trial in people with HIV and excess belly fat, it reduced visceral fat by 15.2% (versus a 5.0% increase on placebo) and lowered triglycerides, without changing blood sugar measures.[10] It is approved only for HIV-associated abdominal fat, not for metabolic syndrome in general.
Unproven “metabolic” peptides
- MOTS-c prevented diet-induced obesity and insulin resistance in mice.[11] There are no published human trials showing benefits for metabolic syndrome.
- AOD-9604, a growth hormone fragment, is marketed for fat loss, but there are no metabolic syndrome trials.
FDA lists both among bulk substances nominated for compounding that raised safety concerns.[12] For a broader look at weight-loss options ranked by evidence, see our best peptides for weight loss guide.
Side effects and practical questions
GLP-1 drugs commonly cause nausea, diarrhea, vomiting and constipation, and carry warnings about gallbladder disease, pancreatitis and thyroid C-cell tumors in rodents.[7][8] Weight usually returns after stopping, so these are typically long-term treatments; see keeping weight off after a GLP-1 and GLP-1 muscle loss.
Questions to ask your clinician:
- Which parts of metabolic syndrome do I have, and which matters most for me?
- Do I qualify for semaglutide or tirzepatide under their approved uses?
- How will we track blood pressure, cholesterol and blood sugar if I start one?
- What diet and activity changes would help most?
